ArticleJournal of human hypertension2010
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Article in Journal of human hypertension, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.Medicine · 2017Pooled it
- Effects of eplerenone on blood pressure and glucose metabolism in Japanese hypertensives with overweight or obesity.Medicine · 2019Trial
- Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.Metabolic syndrome and related disorders · 2015Trial
- Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice.International journal of hypertension · 2019Article
- Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production.The Journal of endocrinology · 2017Review
- VLDL-activated cell signaling pathways that stimulate adrenal cell aldosterone production.Molecular and cellular endocrinology · 2016Article
- Targeting inflammation in metabolic syndrome.Translational research : the journal of laboratory and clinical medicine · 2016Review
- The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Review
- Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.Current hypertension reports · 2014Review
- Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.Cardiovascular diabetology · 2013Article
- Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications.British journal of pharmacology · 2013Review
- Mineralocorticoid receptor antagonists and the metabolic syndrome.Current hypertension reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eplerenone, a selective aldosterone blocker, has become clinically available in Japan since 2007. It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension. However, clinical data on hypertensive patients in Japan are lacking for eplerenone. In this study, we explored the clinical efficacy of eplerenone when it is added to an angiotensin-converting enzyme (ACE) inhibitor or a long-acting calcium channel blocker (CCB) in 68 (31 males, 37 females) Japanese patients with essential hypertension. After adding 50 mg of eplerenone to their basal treatment, blood pressure was significantly reduced at 4 weeks, and further reduced after 24 weeks of eplerenone treatment. Urinary albumin excretion decreased significantly after 24 weeks. There were no significant differences in general biochemical test values or electrolytes, but fasting serum triglycerides were significantly decreased after eplerenone treatment. The serum potassium level showed no significant change during treatment. There were no significant correlations between plasma renin activity or plasma aldosterone concentration (PAC) before eplerenone treatment and blood pressure after eplerenone treatment, showing that the antihypertensive effect of eplerenone is not affected by the patient's renin profile or pretreatment PAC values. Eplerenone was also effective in hypertensive patients with metabolic syndrome. In conclusion, eplerenone, when coadministered with an ACE inhibitor or a long-acting CCB, caused an extremely beneficial antihypertensive effect in Japanese patients with essential hypertension, without few clinically important adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.